These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15138896)

  • 1. Paroxetine in major depression: correlating plasma concentrations and clinical response.
    Normann C; Hörn M; Hummel B; Grunze H; Walden J
    Pharmacopsychiatry; 2004 May; 37(3):123-6. PubMed ID: 15138896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders.
    Yasui-Furukori N; Nakagami T; Kaneda A; Inoue Y; Suzuki A; Otani K; Kaneko S
    Hum Psychopharmacol; 2011 Dec; 26(8):602-8. PubMed ID: 22102561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.
    Lotrich FE; Pollock BG; Kirshner M; Ferrell RF; Reynolds Iii CF
    J Psychiatry Neurosci; 2008 Mar; 33(2):123-30. PubMed ID: 18330458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No difference in adherence to paroxetine between depressed patients with early remission and those with late remission based on monitoring of plasma paroxetine concentrations.
    Yoshimura R; Umene-Nakano W; Ueda N; Ikenouchi-Sugita A; Hori H; Katsuki A; Hayashi K; Miyamoto K; Kodama Y; Nakamura J
    Hum Psychopharmacol; 2010 Aug; 25(6):487-90. PubMed ID: 20725911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
    Tomita T; Yasui-Furukori N; Nakagami T; Tsuchimine S; Ishioka M; Kaneda A; Sugawara N; Kaneko S
    PLoS One; 2014; 9(5):e98099. PubMed ID: 24858363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder.
    Appelhof BC; Brouwer JP; van Dyck R; Fliers E; Hoogendijk WJ; Huyser J; Schene AH; Tijssen JG; Wiersinga WM
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6271-6. PubMed ID: 15579788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression.
    Reis M; Aberg-Wistedt A; Agren H; Höglund P; Akerblad AC; Bengtsson F
    Hum Psychopharmacol; 2004 Jul; 19(5):283-91. PubMed ID: 15252820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos.
    Figueras G; Pérez V; San Martino O; Alvarez E; Artigas F
    Biol Psychiatry; 1999 Aug; 46(4):518-24. PubMed ID: 10459402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.
    Yoshimura R; Umene-Nakano W; Suzuki A; Ueda N; Miyamoto K; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    Hum Psychopharmacol; 2009 Aug; 24(6):489-94. PubMed ID: 19606452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ
    Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
    Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder.
    Ruhé HG; Koster M; Booij J; van Herk M; Veltman DJ; Schene AH
    Psychiatry Res; 2014 Feb; 221(2):155-61. PubMed ID: 24406081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population.
    Wang XC; Xu DJ; Chen GH; Xia Q; Liu LN
    Ther Drug Monit; 2014 Oct; 36(5):612-7. PubMed ID: 24577123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine in the treatment of adolescent major depression.
    Correll CU; Pleak RR
    J Am Acad Child Adolesc Psychiatry; 2002 Nov; 41(11):1269; author reply 1270. PubMed ID: 12410065
    [No Abstract]   [Full Text] [Related]  

  • 16. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
    Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB
    J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine in the treatment of adolescent major depression.
    Silveira R; Jainer AK; Singh R
    J Am Acad Child Adolesc Psychiatry; 2002 Nov; 41(11):1270; author reply 1271. PubMed ID: 12410066
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study.
    Ruhé HG; Booij J; Veltman DJ; Michel MC; Schene AH
    J Clin Psychiatry; 2012 Apr; 73(4):451-9. PubMed ID: 21903032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting.
    Benedetti F; Colombo C; Pirovano A; Marino E; Smeraldi E
    Psychopharmacology (Berl); 2009 Mar; 203(1):155-60. PubMed ID: 18989660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly.
    Bump GM; Mulsant BH; Pollock BG; Mazumdar S; Begley AE; Dew MA; Reynolds CF
    Depress Anxiety; 2001; 13(1):38-44. PubMed ID: 11233459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.